Form 4: Precipio Director Kathleen LaPorte Reports Stock Option Repricing

Director Kathleen LaPorte reports repricing of stock options to $6.56 per share, effective August 31, 2024.

Summary

• Kathleen LaPorte, a director at Precipio, Inc., filed a Form 4 on September 6, 2024, reporting changes in beneficial ownership due to a stock option repricing.
• The repricing, approved by the Board of Directors on August 30, 2024, became effective on August 31, 2024.
• The exercise price of several stock options was adjusted to $6.56 per share, reflecting the fair market value of Precipio's common stock on the effective date.
• The repriced options will revert to their original exercise price if LaPorte's service with the Issuer is terminated with cause or by LaPorte, or if the option is exercised, prior to the first anniversary of the effective date.
• The stock options were issued under the company's Amended and Restated 2017 Stock Option and Incentive Plan and become exercisable according to the vesting schedule in the award agreement.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a stock option repricing. The impact on the company is neither explicitly positive nor negative.

Positives

• The repricing of stock options could incentivize the director to remain with the company.
• The new exercise price reflects the fair market value of the company's common stock on the effective date.

Risks

• The repriced options could revert to their original exercise price if certain conditions are met before the first anniversary of the effective date, potentially reducing the incentive for the director.

Industry Context

Option repricing is a common practice to incentivize employees and executives, especially when the stock price has declined. It ensures that options remain a valuable part of the compensation package.

Comparison to Industry Standards

• Stock option repricing is a fairly common practice in publicly traded companies, particularly in the technology and biotech sectors, to maintain the incentive value of options when the stock price has fallen below the original exercise price.
• Companies like Zynerba Pharmaceuticals and Titan Pharmaceuticals have also undertaken similar repricing actions to motivate their employees and retain key personnel.
• The specific terms of the repricing, such as the new exercise price and vesting schedules, are generally tailored to the individual company's circumstances and the prevailing market conditions.

Stakeholder Impact

• The repricing of stock options may have a positive impact on the director's motivation and alignment with shareholder interests.
• Shareholders may view the repricing as a necessary measure to retain key personnel and incentivize performance.

Key Dates

Keywords

stock options, Precipio, repricing, director, Form 4, beneficial ownership, LaPorte, incentive plan